San Francisco / Budapest / Bratislava / Amsterdam / Oakland / Baltimore / Sydney / Kiev / Prague / Lisbon / /
Company
Bauman AE / Safren SA / J Manag Care Pharm / Incident HIV / Dove Press / Dove Medical Press Limited. / HCV / Hepatitis C / Formulary / Creative Commons / /
Continent
Europe / /
Country
Hungary / Netherlands / Norway / France / Canada / Australia / Portugal / Slovakia / United Kingdom / Germany / Belgium / Russia / United States / Luxembourg / Ukraine / Czech Republic / / /
Event
FDA Phase / Business Partnership / /
Facility
University of New South Wales / University of Hamburg / Heathcote / Charles University / Kirby Institute / / /
IndustryTerm
important tools / treatment of hepatitis C / transportation / prevention of hepatitis C / drug services / treatment systems / carrier pool / therapy for hepatitis C / AIDS prevention / these and other services / pretreatment management / treatment of HCV / HCV care / mass media / therapies for hepatitis C / HCV treatment / care for hepatitis C / medical and mental health services / Hepatitis Treatment / hepatitis C treatment / patient / prevention of HIV / HCV prevention / clinical management / treatment services / AIDS Care / mass media campaign / treatment for hepatitis C / drug treatment services / health insurance schemes / /
MedicalCondition
Hickman M. Can hepatitis C / HIV / cirrhosis / hepatitis B / recently acquired hepatitis C / liver cirrhosis / liver disease / hepatic decompensation / low pretreatment viremia / acute hepatitis C / chronic HCV / Gold J. Hepatitis C / superinfection / psychiatric disorders / virus infection / AIDS / HIV/AIDS / infection / depression / rash / drug addiction / primary liver cancer / acquired immune deficiency syndrome / hepatitis C / detectable hepatitis C / HIV infection / heroin users / psychiatric diseases / disease / Gane E. Future hepatitis C / chronic hepattis C / liver cancer / different epidemic settings / drug abuse / infectious diseases / Mauss S. Hepatitis C / et al. Hepatitis C / acute infection / anemia / chronic hepatitis C / early hepatitis C / tuberculosis / /
World Health Organization / Publications Office / Government of the Czech Republic / Institute for Postgraduate Medical Education in Prague / First Faculty of Medicine / Internal Grant Agency / European Union / National Monitoring Centre for Drugs and Drug Addiction / Ministry of Health / University of Hamburg / Hamburg / Charles University in Prague / Faculty of Medicine / European Association of the Study of the Liver / Department of Addictology / University of New South Wales / Kirby Institute for Infection and Immunity / Department of General Practice / Second Faculty of Medicine / Sydney Area Health Service / European Monitoring Centre for Drugs and Drug Addiction / /
Person
Ali R. Oral / Viktor Mravčík / Mohd Hanafiah / Van Vlierberghe / / /
Position
Author / General Practice / model of human immunodeficiency virus antiretroviral adherence research / Cooreman MP / Schoondermark-Van de Ven EM / multidisciplinary group model for the treatment / /
Product
peginterferon / ribavirin / If drug / HCV / IL28B / /
PPAfactors-associated-with-hepatitis-c-treatment-uptake--adhere